Table 3 Magnitude of antibody responses against immunoreactive Hp-specific antigens as measured by Western immunoblotting in sera of 60 anti-Hp(+) patients with multiple sclerosis (MS), including 41 relapsing-remitting (RRMS) patients and 19 secondary progressive (SPMS) patients, 33 anti-Hp(+) healthy controls (HC), 14 anti-Hp(+) patients with Parkinson’s disease (PD) and 10 anti-Hp(+) patients with Alzheimer’s disease (ALZ).

From: Immune responses against Helicobacter pylori-specific antigens differentiate relapsing remitting from secondary progressive multiple sclerosis

Reactive band

All MS (n = 60)

RRMS (n = 41)

SPMS (n = 19)

HC (n = 33)

PD (n = 14)

ALZ (n = 10)

p (RRMS vs SPMS)

p (All MS vs HC)

p (RRMS vs HC)

p (SPMS vs HC)

p (MS vs PD)

p (RRMS vs PD)

p (SPMS vs PD)

p (MS vs ALZ)

p (RRMS vs ALZ)

p (SPMS vs ALZ)

p120 – CagA

103.8 ± 33.7

103.7 ± 35.2

104.1 ± 31.7

76.6 ± 42

95.7 ± 37.7

66.7 ± 26.4

ns

0.005 ‡

0.010 ‡

0.019 ‡

ns

ns

ns

0.002 ‡

0.002 ‡

0.004 ‡

p95 – VacA

38.1 ± 30.9

38.3 ± 33.4

37.8 ± 30.2

21.3 ± 5.9

32.2 ± 12.9

30.7 ± 16.2

ns

0.051‡

ns

ns

ns

ns

ns

ns

ns

ns

p75

36 ± 18.1

35.5 ± 14.8

36.5 ± 27.6

26.3 ± 12.6

24.5 ± 17.9

—

ns

ns

ns

ns

ns

ns

ns

N/A

N/A

N/A

p67

49.2 ± 40

55.1 ± 41.9

41.1 ± 37.2

43.5 ± 34.6

79 ± 40.8

42.3 ± 36.8

ns

ns

ns

ns

ns

ns

0.036 ‡

ns

ns

ns

p66 – UreB

45.7 ± 25.3

47.6 ± 27.6

42.2 ± 21.1

65.2 ± 31.7

59 ± 32

45.4 ± 35.6

ns

0.013 ‡

0.040 ‡

0.010 ‡

ns

ns

ns

ns

ns

ns

p54-flagellin

29.8 ± 16.9

27.8 ± 17.4

31 ± 17.9

55.9 ± 39.6

66.8 ± 31.2

42.8 ± 17.6

ns

0.046 ‡

0.067‡

0.070‡

0.032 ‡

0.035 ‡

0.039 ‡

ns

ns

ns

p50

31.8 ± 16.1

32.9 ± 18.5

30.8 ± 13.8

46.9 ± 22.4

34.5 ± 11.1

33.3 ± 15.7

ns

0.016 ‡

0.051‡

0.014 ‡

ns

ns

ns

ns

ns

ns

p41

29.1 ± 15.7

30.6 ± 22

28.4 ± 13

37.5 ± 22.4

41.1 ± 29.3

32 ± 13.5

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

p33

73.3 ± 35.8

73.9 ± 42.1

72.3 ± 27.6

74.7 ± 34.3

53 ± 42.1

42 ± 0*

ns

ns

ns

ns

ns

ns

ns

N/A

N/A

N/A

p30

35.1 ± 23

22.5 ± 9.8

52 ± 26.3

29.3 ± 13.5

27.9 ± 12.5

37.7 ± 10.1

ns

ns

ns

ns

ns

ns

ns

ns

0.077‡

ns

p29 – UreA

36.3 ± 22.4

30.1 ± 20

42 ± 23.7

64.1 ± 49.1

60.8 ± 30.1

34 ± 16.8

ns

0.026 ‡

0.010 ‡

0.092‡

0.022 ‡

0.008 ‡

0.096‡

ns

ns

ns

p26

56.3 ± 35.5

52.8 ± 34

62.8 ± 38.9

53.5 ± 34

61.6 ± 33.7

46.1 ± 31.7

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

p19

31.9 ± 14

31.4 ± 14.7

33.2 ± 13.2

42.5 ± 32.8

47.5 ± 24.2

25.6 ± 16.3

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

p17

34.6 ± 17.3

34.4 ± 17.9

35 ± 17.2

39 ± 21.8

38.8 ± 15.8

34.8 ± 26.3

ns

ns

ns

ns

ns

ns

ns

ns

ns

ns

  1. Data on the magnitude of antibody responses are expressed as mean ± standard deviation arbitratry units (AU) (see methods). ‡p-values were calculated using 2-tailed t-test for Equality of Means, equal variances were not assumed. p-values < 0.05 are shown in bold; *, n = 1; p-values with a statistical tendency (<0.1) are also shown. Abbreviations: CagA, protein from cytotoxin-associated gene A; FSH, Flagellar Sheath Protein; ns, not significant; N/A, non-applicable; UreA, urease A; UreB, urease B; VacA, vacuolating cytotoxin A.
Back to article page